Published in Volume
98, Issue 7 (October 1, 1996)
J Clin Invest. 1996;98(7):1519–1526.
doi:10.1172/JCI118943.
Copyright ©
1996, The American Society for
Clinical Investigation.
Research Article
A human non-XLA immunodeficiency disease characterized by blockage of B cell development at an early proB cell stage.
E Meffre, F LeDeist, G de Saint-Basile, A Deville, M Fougereau, A Fischer and C Schiff
Centre d'Immunologie de Marseille-Luminy, Marseille, France.
Published October 1, 1996
We report a detailed analysis of a B cell defect affecting a patient girl born from first cousin parents, characterized by a severe non-X-linked agammaglobulinemia with a total absence of CD19- cells in the periphery. In the bone marrow, CD19 expression was also highly impaired, resulting in the absence of both B and preB compartments. By contrast, CD34+CD10+, CD34psiL+, and some CD19+CD10+ mostly CD34+ early proB cells were present, although diminished. Semiquantitative RT-PCR analysis performed on mononuclear bone marrow cells indicated that lambda-like, VpreB, Rag-1, Rag-2, and TdT transcripts expressed during proB cell stages were found at normal levels whereas E2A, CD10, Syk, Pax-5, CD19, Igalpha, Igbeta, VH-Cmu, and Vkappa-Ckappa transcripts characteristic of later stages were severely depressed. This phenotype resembles that of Pax-5 knock-out mice, but since the coding sequence of the patient Pax-5 cDNA was shown to be normal, the defect might rather result from an altered regulation of this gene. All these data indicate that the patient suffers from a new genetic defect that results in an arrest of differentiation within the proB cell compartment, i.e., earlier than X-linked agammaglobulinemia, before the onset of Ig gene rearrangements.